Scientific Committee on Consumer Safety Delivers Verdict on Benzyl Salicylate: A Closer Look at Safety and Usage in Cosmetics

The Scientific Committee on Consumer Safety (SCCS) has released its conclusive opinion on Benzyl Salicylate (CAS No. 118-58-1, EC No. 204-262-9), delving into its safety profile and recommended usage concentrations in cosmetic formulations.

In light of comprehensive data analysis and acknowledging concerns surrounding potential endocrine disrupting properties, the SCCS has affirmed the safety of Benzyl Salicylate within the maximum concentrations outlined in the dossier submitted by the Benzyl Salicylate Consortium. The SCCS emphasizes its commitment to thorough evaluation, ensuring that consumers can confidently use products containing Benzyl Salicylate at concentrations specified in Table 1 of the opinion.

Benzyl Salicylate Table

Alternatively, the SCCS clarifies that, in their assessment, the maximum concentration deemed safe for Benzyl Salicylate in cosmetic products aligns with the concentrations provided in the aforementioned dossier submission.

Addressing scientific concerns, the SCCS acknowledges data suggesting an endocrine mode of action associated with Benzyl Salicylate. However, crucially, there is no concrete evidence indicating that this mode of action translates into tangible endocrine effects.

It is imperative to note that the SCCS's jurisdiction is limited to safety assessments and does not extend to environmental considerations. Consequently, the safety evaluation provided does not encompass the environmental impact of Benzyl Salicylate.

This verdict from the SCCS underscores the meticulous approach taken in evaluating cosmetic ingredients, ensuring that formulations meet rigorous safety standards while allowing consumers to enjoy the benefits of innovative and effective products. As the cosmetic industry continues to evolve, safety assessments by esteemed committees like the SCCS play a pivotal role in maintaining consumer confidence and product integrity.